PZ Cormay S.A.

Equities

CRM

PLCMRAY00029

Medical Equipment, Supplies & Distribution

Market Closed - Warsaw S.E. Other stock markets 11:55:52 2024-05-02 am EDT			5-day change	1st Jan Change
0.59 ^PLN	+0.34%		-2.32%	+0.34%

2023	PZ Cormay S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	PZ Cormay S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

PZ Cormay S.A. announced that it has received funding from Ipopema Towarzystwo Funduszy Inwestycyjnych S.A..

September 28, 2015

PZ Cormay S.A. (WSE:CRM) announced a private placement of series K shares on September 29, 2015. Returning investor TOTAL Fundusz Inwestycyjny Zamkniety, a fund managed by Ipopema Towarzystwo Funduszy Inwestycyjnych S.A. acquired 6.6% direct and indirect stake in the company to hold 22.96% stake. Investor exercised its pre-emptive right to subscribe shares of the company.

Latest news about PZ Cormay S.A.

PZ Cormay S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
PZ Cormay S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-15	CI
PZ Cormay S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-19	CI
PZ Cormay S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
PZ Cormay S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-09	CI
PZ Cormay S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-20	CI
PZ Cormay S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-22	CI
PZ Cormay S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Pz Cormay S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-09-10	CI
Pz Cormay S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-23	CI
PZ Cormay S.A. acquired unknown minority stake in Orphée SA for CHF 1.2 million.	20-11-16	CI
Pz Cormay S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-06	CI
PZ Cormay S.A. completed the acquisition of 0.54% stake in Orphée SA for PLN 0.37 million.	20-02-05	CI
PZ Cormay S.A. made a tender offer to acquire remaining 2.9% stake in Orphée SA for PLN 2 million.	19-12-10	CI
PZ Cormay S.A. agreed to acquire remaining 11.6% stake in Orphée SA for PLN 7.8 million.	19-09-04	CI
PZ Cormay S.A. announced that it has received PLN 7 million in funding	18-10-10	CI
PZ Cormay S.A. announced that it expects to receive PLN 7 million in funding	18-08-06	CI
Cormay Seeks To Divest	17-12-16	CI
PZ Cormay S.A. cancelled the acquisition of an additional 12.95% stake in Orphée SA from TTL 1 SP Z O O.	17-05-17	CI
Wesolowski To Reportedly Acquire PZ Cormay	16-06-24	CI
PZ Cormay S.A. signed an agreement to acquire additional 12.95% stake in Orphée SA from TTL 1 SP Z O O for PLN 10 million.	16-05-17	CI
PZ Cormay S.A. announced that it has received funding from Ipopema Towarzystwo Funduszy Inwestycyjnych S.A..	15-09-28	CI
TTL 1 SP Z O O and another shareholder completed the acquisition of 27% stake in Orphée SA from PZ Cormay S.A..	15-03-03	CI
TTL 1 SP Z O O and another shareholder agreed to acquire 27% stake in Orphée SA from PZ Cormay S.A. for PLN 20.8 million.	15-02-25	CI
TTL 1 SP Z O O acquired 3.92% stake in PZ Cormay S.A..	14-07-22	CI

Chart PZ Cormay S.A.

Duration

Period

More charts

Company Profile

PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
PZ CORMAY S.A.	+0.34%	12.37M
BIOMÉRIEUX	-1.89%	12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.68B
DIASORIN S.P.A.	-1.31%	5.29B
LANTHEUS HOLDINGS, INC.	+21.82%	5.24B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
10X GENOMICS, INC.	-50.89%	3.29B
ANDON HEALTH CO., LTD.	+6.42%	2.6B
VITROLIFE AB	-10.02%	2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.29%	1.79B

Diagnostic & Testing Substances